Back

Efficacy and harms associated with polypills for primary and secondary prevention of cardiovascular disease: a systematic review and meta-analysis.

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Hypertension pharmacotherapy updates Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Adrian V Hernandez

University of Connecticut, Storrs (United States of America)

3 More presentations in this session

Presentation thumbnail
Impact of systolic blood pressure on ischemic and bleeding events and the efficacy and safety of rivaroxaban monotherapy: a post-hoc analysis of the AFIRE trial
Doctor S. Yamanaka (Sendai, JP)
Abstract Slides Video
Presentation thumbnail
Genetic inhibition of angiopoietin-like protein 3, 4, and 8 on cardiovascular disease risk
Professor X. Hua (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Community pharmacist intervention to enhance adherence in patients initiating cardiovascular medication: the PHARM-ADHERE randomized controlled trial
Miss A. Watteyne (Ghent, BE)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertension pharmacotherapy updates

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
The cardiovascular polypill: simplicity to tackle a complex problem
thumbnail
Congress Presentation
The cardiovascular polypill strategy (acetyl salicylic acid, atorvastatin, ramipril) as baseline treatment after a cardiovascular event supported by compelling evidence: a global expert consensus
thumbnail
Congress Presentation
Combination of moderate-intensity statins and ezetimibe versus high-intensity statins alone for primary prevention of cardiovascular events

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources